



(Incorporated in the Cayman Islands with Limited Liability)

Stock Code: 0575

24 February 2017

ANNOUNCEMENT




Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PROFIT WARNING

SUMMARY

This announcement is made by the Company in compliance with the disclosure requirements under Rule 13.09 of the HK Listing Rules and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Directors wish to inform the shareholders of the Company and potential investors that based on the preliminary assessment of the information currently available to the Board, they expect that the Group will record a loss attributable to the equity holders of the Company for the year ended 31 December 2016 of between US\$2 million (or approximately HK\$15.60 million) to US\$3 million (or approximately HK\$23.40 million) notwithstanding that there was a profit attributable to the equity holders of the Company of US\$15.96 million (or approximately HK\$124.49 million) for the first half of 2016. The loss in the second half is mainly attributable to (i) the amortisation cost of US\$14.14 million (or approximately HK\$110.29 million) of Fortacin™, which is a non-cash item; and (ii) the development and commercialisation expenses of US\$1.82 million (or approximately HK\$14.20 million) relating to the launch of Fortacin™. However, it is expected that the loss attributable to the equity holders of the Company for the year ended 31 December 2016 will be significantly lower than the loss attributable to the equity holders of the Company of approximately US\$9.34 million (or approximately HK\$72.85 million) for the corresponding year in 2015.



The financial year concluded on 31 December 2016 and, consequently, the Company is still in the process of finalising the Group's annual results. The information contained in this announcement is only an initial assessment by the Directors based on a preliminary review of the currently available and unaudited management accounts and is not based on any financial data or information that has been audited or reviewed by the Group's auditor. The Company will publish its audited annual results for the year ended 31 December 2016 as soon as practicable, but not later than 31 March 2017.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Regent Pacific Group Limited (the "**Company**") and collectively with its subsidiaries, the "**Group**") in compliance with the disclosure requirements under Rule 13.09 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**HK Listing Rules**") and the Inside Information Provisions (as defined under the HK Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The directors (the "**Directors**" or the "**Board**") of the Company wish to inform the shareholders of the Company and potential investors that based on the preliminary assessment of the information currently available to the Board, they expect that the Group will record a loss attributable to the equity holders of the Company for the year ended 31 December 2016 of between US\$2 million (or approximately HK\$15.60 million) to US\$3 million (or approximately HK\$23.40 million) notwithstanding there was a profit attributable to the equity holders of the Company of US\$15.96 million (or approximately HK\$124.49 million) for the first half of 2016. However, it is expected that the loss attributable to the equity holders of the Company for the year ended 31 December 2016 will be significantly lower than the loss attributable to the equity holders of the Company of approximately US\$9.34 million (or approximately HK\$72.85 million) for the corresponding year in 2015.

The loss in the second half of 2016 is mainly attributable to (i) the amortisation cost of US\$14.14 million (or approximately HK\$110.29 million) of Fortacin™, which is a non-cash item; and (ii) the development and commercialisation expenses of US\$1.82 million (or approximately HK\$14.20 million) relating to the launch of Fortacin™.

The Company continues to be debt free with approximately US\$7.68 million (or approximately HK\$59.90 million) in cash and listed securities as at 31 December 2016.

The financial year concluded on 31 December 2016 and, consequently, the Company is still in the process of finalising the Group's annual results. The information contained in this announcement is only an initial assessment by the Directors based on a preliminary review of the currently available and unaudited management accounts and is not based on any financial data or information that has been audited or reviewed by the Group's auditor. The Company will publish its audited annual results for the year ended 31 December 2016 as soon as practicable, but not later than 31 March 2017.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

Note: Unless otherwise specified herein, amounts denominated in US\$ have been translated, for the purpose of illustration only, into HK\$ using the exchange rate of US\$1.00 = HK\$7.80.

On Behalf of the Board of
Regent Pacific Group Limited

Jamie Gibson
Director

Directors of the Company:

James Mellon (*Chairman*)^{*}
Jamie Gibson (*Chief Executive Officer*)
David Comba[#]
Julie Oates[#]
Mark Searle[#]
Jayne Sutcliffe^{*}

^{*} *Non-Executive Directors*

[#] *Independent Non-Executive Directors*

Hong Kong, 24 February 2017